NRF2 signalling in endometriosis: A hormone-independent axis for fertility-preserving therapeutic innovation
- 1The Second Clinical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, 510120, China; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China
- 2The Second Clinical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou, 510120, China; The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, 510120, China; Corresponding authors at: The Second Clinical College of Guangzhou University of Traditional Chinese Medicine, Guangzhou 510120, China.
Abstract
Endometriosis is a chronic inflammatory disease characterised by pain, infertility and recurrence. Current pharmacological management relies largely on hormonal suppression, which can reduce pain and disease activity but does not eradicate ectopic lesions, and symptoms often recur after treatment withdrawal. Adverse effects and incomplete responses further limit long-term use. Because hormonal therapies suppress ovulation and menstruation without improving spontaneous fertility, they are unsuitable for patients seeking pregnancy, underscoring the need for non-hormonal strategies that control lesions while preserving reproductive function. Recurrent bleeding, erythrocyte degradation and iron accumulation create an oxidative microenvironment linking ferroptosis dysregulation, chronic inflammation and defective immune clearance. NRF2 coordinates antioxidant defence, lipid-peroxide removal, iron and haem handling, and inflammatory and immune responses, but its effects are context dependent. To organise these divergent findings, we propose a testable framework of redox-adapted and redox-exhausted lesion states and consider how redox capacity, cellular compartment, intervention intensity and timing may shape NRF2-directed interventions. This review integrates NRF2 regulation with evidence on oxidative stress, ferroptosis, inflammation, immunity and reproductive-tissue protection in endometriosis. We distinguish direct disease evidence from mechanistic extrapolation, evaluate pharmacological, immune-informed and materials-based approaches for selective or local NRF2 modulation, and discuss cell-specific effects and cycle-dependent reproductive-tissue vulnerability. We further define key translational requirements, including human-lesion validation, predictive biomarkers, therapeutic thresholds, reproductive-safety assessment and cell-selective or lesion-restricted delivery. This framework provides testable questions and a staged basis for future preclinical and early translational studies.
Related
- Endometriosis from Initiation to Innovation: Immune Microenvironments, Clonal Lesion Biology, and the Emerging Therapeutic Pipeline
- Nonhormonal management of endometriosis: Role of dopamine D2 receptor agonists in preserving fertility and ovarian function.
- Editorial: Decoding cancer complexity with artificial intelligence and molecular level studies: informatics-driven approaches for therapeutic innovation
- Federated learning for privacy-preserving opportunistic screening of lumbar-spine DXA-defined osteoporotic-level bone mineral density using chest radiographs: A multi-center independent validation study
- Cellular Phenotypic Changes in Endometriosis: Pathogenetic Mechanisms and Therapeutic Implications.
BibTeX
@article{chen2026nrf2,
title = {{NRF2 signalling in endometriosis: A hormone-independent axis for fertility-preserving therapeutic innovation}},
author = {Shen Chen and Yun Lu and Luxuan Wang and Anli Weng and Yuxi Miao and Li Feng and Zhiqi Wang and Mingtao Xu and Xuefang Liang and Yongxia Wang},
journal = {Pharmacological Research},
year = {2026},
month = nov,
doi = {10.1016/j.phrs.2026.108453},
url = {https://doi.org/10.1016/j.phrs.2026.108453},
note = {CC BY},
}
RIS
TY - JOUR
TI - NRF2 signalling in endometriosis: A hormone-independent axis for fertility-preserving therapeutic innovation
AU - Shen Chen
AU - Yun Lu
AU - Luxuan Wang
AU - Anli Weng
AU - Yuxi Miao
AU - Li Feng
AU - Zhiqi Wang
AU - Mingtao Xu
AU - Xuefang Liang
AU - Yongxia Wang
PY - 2026
DA - 2026/11/04
JO - Pharmacological Research
DO - 10.1016/j.phrs.2026.108453
UR - https://doi.org/10.1016/j.phrs.2026.108453
AB - Endometriosis is a chronic inflammatory disease characterised by pain, infertility and recurrence. Current pharmacological management relies largely on hormonal suppression, which can reduce pain and disease activity but does not eradicate ectopic lesions, and symptoms often recur after treatment withdrawal. Adverse effects and incomplete responses further limit long-term use. Because hormonal therapies suppress ovulation and menstruation without improving spontaneous fertility, they are unsuitable for patients seeking pregnancy, underscoring the need for non-hormonal strategies that control lesions while preserving reproductive function. Recurrent bleeding, erythrocyte degradation and iron accumulation create an oxidative microenvironment linking ferroptosis dysregulation, chronic inflammation and defective immune clearance. NRF2 coordinates antioxidant defence, lipid-peroxide removal, iron and haem handling, and inflammatory and immune responses, but its effects are context dependent. To organise these divergent findings, we propose a testable framework of redox-adapted and redox-exhausted lesion states and consider how redox capacity, cellular compartment, intervention intensity and timing may shape NRF2-directed interventions. This review integrates NRF2 regulation with evidence on oxidative stress, ferroptosis, inflammation, immunity and reproductive-tissue protection in endometriosis. We distinguish direct disease evidence from mechanistic extrapolation, evaluate pharmacological, immune-informed and materials-based approaches for selective or local NRF2 modulation, and discuss cell-specific effects and cycle-dependent reproductive-tissue vulnerability. We further define key translational requirements, including human-lesion validation, predictive biomarkers, therapeutic thresholds, reproductive-safety assessment and cell-selective or lesion-restricted delivery. This framework provides testable questions and a staged basis for future preclinical and early translational studies.
SN - 1096-1186
ER -